Ad26.COV2.S
E241393
Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ad26.COV2.S canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190788 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ad26.COV2.S Context triple: [Janssen COVID-19 Vaccine, alsoKnownAs, Ad26.COV2.S]
-
A.
Omicron
Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
-
B.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
-
C.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
D.
Phage Group
The Phage Group was an informal collective of mid-20th-century molecular biologists who used bacteriophages to uncover fundamental principles of genetics and helped lay the foundations of molecular biology.
-
E.
TMV
TMV is the stock ticker symbol under which TeamViewer, a global provider of remote connectivity and remote access software, is traded on financial markets.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ad26.COV2.S Target entity description: Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
-
A.
Omicron
Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
-
B.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
-
C.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
D.
Phage Group
The Phage Group was an informal collective of mid-20th-century molecular biologists who used bacteriophages to uncover fundamental principles of genetics and helped lay the foundations of molecular biology.
-
E.
TMV
TMV is the stock ticker symbol under which TeamViewer, a global provider of remote connectivity and remote access software, is traded on financial markets.
- F. None of above. chosen
Statements (52)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
adenovirus vector vaccine ⓘ single-dose vaccine ⓘ viral vector vaccine ⓘ |
| administrationSite | deltoid muscle ⓘ |
| adverseEventOfSpecialInterest |
Guillain–Barré syndrome
ⓘ
thrombosis with thrombocytopenia syndrome ⓘ |
| ageIndication | adults 18 years and older ⓘ |
| antigen | SARS-CoV-2 spike protein ⓘ |
| ATCCode | J07BX03 ⓘ |
| boosterOption |
heterologous booster allowed in some jurisdictions
ⓘ
homologous booster allowed in some jurisdictions ⓘ |
| brandName |
Janssen COVID-19 Vaccine
ⓘ
Jcovden ⓘ |
| clinicalTrialPhase | Phase III completed ⓘ |
| coldChainRequirement | standard vaccine cold chain ⓘ |
| containsGeneticMaterial | DNA ⓘ |
| countryOfOrigin | United States of America ⓘ |
| developer |
Janssen Pharmaceuticals
ⓘ
Janssen Pharmaceuticals ⓘ
surface form:
Janssen Vaccines
Johnson & Johnson ⓘ |
| doesNotContain |
live SARS-CoV-2 virus
ⓘ
mRNA ⓘ |
| doseRegimen | single dose ⓘ |
| efficacyAgainstSevereCOVID19 | approximately 85% in Phase III trial ⓘ |
| efficacyAgainstSymptomaticCOVID19 | approximately 66% in global Phase III trial ⓘ |
| EMAAuthorizationDate | 2021-03-11 ⓘ |
| EMAAuthorizationType | conditional marketing authorization ⓘ |
| EMAStatus | Conditional marketing authorization granted ⓘ |
| EUAStatus | Emergency Use Authorization granted by US FDA ⓘ |
| intendedUse | prevention of COVID-19 infection ⓘ |
| manufacturer |
Janssen Biotech
ⓘ
Janssen Pharmaceuticals ⓘ
surface form:
Janssen Pharmaceuticals Companies of Johnson & Johnson
|
| platform | recombinant adenovirus serotype 26 vector ⓘ |
| regimenType | single primary dose with optional booster ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| schedule | 0.5 mL single intramuscular dose ⓘ |
| storageRequirement | refrigeration ⓘ |
| storageTemperature | 2–8 °C ⓘ |
| targetDisease |
COVID-19 pandemic
ⓘ
surface form:
COVID-19
|
| targetVirus | SARS-CoV-2 ⓘ |
| technologyClass | viral vector-based vaccine ⓘ |
| trialDesign | randomized, double-blind, placebo-controlled ⓘ |
| trialName | ENSEMBLE ⓘ |
| USFDAEUAInitialDate | 2021-02-27 ⓘ |
| USFDAEUARestrictionDate | 2022-05-05 ⓘ |
| USFDAEUARestrictionReason | risk of thrombosis with thrombocytopenia syndrome ⓘ |
| USFDAEUAStatus | Authorization limited and later restricted ⓘ |
| USFDAEUAType | Emergency Use Authorization ⓘ |
| vectorType | non-replicating adenovirus vector ⓘ |
| WHOEULDate | 2021-03-12 ⓘ |
| WHOStatus | Emergency Use Listing granted ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ad26.COV2.S Description of subject: Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
human adenovirus serotype 26